The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).
Colin D. Weekes
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Laetitia E. Lamberts
Research Funding - Genentech
Mitesh J. Borad
No relevant relationships to disclose
Johannes Voortman
Research Funding - Genentech
Robert R. McWilliams
No relevant relationships to disclose
Jennifer Robinson Diamond
No relevant relationships to disclose
Elisabeth De Vries
Research Funding - Genentech
Henk M.W. Verheul
Research Funding - Genentech
Christopher Hanyoung Lieu
No relevant relationships to disclose
Huibin Yue
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Yulei Wang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Suzie Scales
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Divya Samineni
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Flavia Brunstein
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
George P. Kim
No relevant relationships to disclose